TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A 2026 paper in The Lancet Healthy Longevity argues that sarcopenia and age-related mobility loss should be understood as problems of the aging motor system, which includes the brain, spinal cord, nerves and muscles. The authors propose changes to assessment and research, but say the suggested measures have not yet been shown to outperform current screening or improve outcomes.
A paper published in The Lancet Healthy Longevity argues that age-related weakness and mobility loss should be understood as problems of the whole motor system, not simply the result of shrinking muscles. The authors say the proposal could change how clinicians assess sarcopenia, but acknowledge that their suggested additional tests have not yet been shown to improve outcomes or outperform existing screens.
The paper, by Lucas B. R. Orssatto and colleagues, says the motor system includes the brain and spinal cord, nerves and their connections to muscles, as well as the muscles themselves. With aging, movement planning, nerve signaling, balance and position sense may all change, potentially reducing how effectively the body activates muscle. The authors argue that this broader account better fits the evidence than treating weakness as a direct consequence of muscle loss alone.
Current sarcopenia assessment has already moved beyond muscle size: grip strength, gait speed and chair-stand performance are used because they predict outcomes such as falls and disability better than muscle mass does, the report says. The authors point to evidence that muscle loss explains only a modest share of declining strength, and that people with similar muscle amounts can have different strength and mobility. They also note that exercise can improve strength and mobility without measurable increases in muscle mass.
The researchers propose that international groups responsible for diagnostic criteria consider a five-point research and clinical agenda. In primary care, they suggest looking beyond whether a person can rise from a chair to how quickly they do it, and paying attention to unsteadiness during sustained effort, hand dexterity and changes in walking while talking. They also recommend closer examination when weakness is asymmetric, develops rapidly or appears out of proportion to muscle loss. These are proposals, not validated replacements for current assessments.
A Broader Way to Assess Weakness
The argument matters because mobility and independence depend on more than muscle bulk. If weakness can arise partly from changes in nerve signaling, coordination or balance, an approach focused mainly on building muscle may miss factors that affect a person’s daily function. The authors say a wider model could support more individualized assessment and direct research toward treatments that target movement and strength, rather than muscle size alone.
The stakes are substantial for older adults and health services. The source report says sarcopenia affects up to 29% of community-dwelling older adults, with higher rates in hospitals and residential care and among people with frailty or multiple health conditions. It also cites Australian figures of 253,800 fall-related hospitalizations in 2024–25 and 6,722 deaths following falls in the preceding year. Those figures describe Australia, not the global burden, and do not establish that the proposed motor-system approach would reduce falls.
For clinicians, the paper’s immediate contribution is a challenge to what gets measured and investigated when a patient reports getting weaker. Its proposed observations may prompt broader evaluation, including medication review, but the paper does not establish that adding them will produce better care. The authors explicitly call for practical tests to be validated before they are adopted as routine screening tools.
Products Worth Considering
BowFlex Results Series SelectTech 552 Adjustable Dumbbell
Garmin Forerunner 570 GPS Running Smartwatch, 47mm, Aluminum, Black
Philips Sonicare DiamondClean Smart 9300 Electric Toothbrush, Black
As an affiliate, we earn on qualifying purchases.
How Sarcopenia Assessment Has Shifted
Sarcopenia refers to substantial loss of muscle, strength and physical function associated with aging. The Medical Xpress report says Australian primary care received a proposed screening, assessment and management algorithm earlier in 2026, published in the Australian Journal of General Practice. That development has brought renewed attention to how primary care identifies poor muscle health.
At the same time, diagnostic emphasis has shifted from muscle mass toward measures of function, including grip strength, walking speed and chair stands. The new paper argues that clinical thinking about the cause has not kept pace: muscle remains the main focus even though strength and mobility do not track muscle quantity consistently. The authors’ article, “Reframing sarcopenia as a disease of the ageing motor system,” was published in 2026 and carries DOI 10.1016/j.lanhl.2026.100898.
The report also describes falls as a major consequence of mobility problems in Australia, citing falls as the leading cause of injury-related hospitalization and death there. These national statistics provide a reason to improve prevention and assessment, but they do not show that sarcopenia or motor-system changes account for every fall.
“Reframing sarcopenia as a disease of the ageing motor system”
— Lucas B. R. Orssatto and co-authors, in their paper in The Lancet Healthy Longevity
Tests Still Need Validation
The proposed assessment changes have not yet been shown to beat existing screens in predicting outcomes or reducing costs, according to the authors. The report also says access to neuromuscular expertise varies across primary care. It remains unclear which additional observations would be practical and reliable enough for routine use, or whether identifying motor-system changes would lead to treatments that preserve mobility more effectively.
The paper presents a model and research agenda, not proof that nervous-system changes explain a particular person’s weakness or that muscle-focused care should be abandoned. The source material does not provide the full details of all five proposed agenda points, nor does it report results from a clinical trial testing the approach. The Australian fall figures also cannot establish how much of the national burden is attributable to sarcopenia.
Validation and Clinical Trials Ahead
The authors call for investment in practical, validated tests that clinicians can use, guidelines that support a staged assessment and trials measuring nerve-related as well as muscle-related outcomes. Those steps would help determine whether a broader motor-system assessment adds useful information beyond current measures and whether it changes care or patient outcomes.
For now, clinicians and guideline groups can consider the paper’s proposals while established screening and clinical judgment remain in place. The next key evidence will be validation studies and trials; the source report does not give a timetable for those studies or say when diagnostic groups will review their criteria.
Key Questions
What does the paper say causes age-related weakness?
The authors argue that weakness may reflect changes across the whole motor system, including the brain, spinal cord, nerves, balance and muscles. They do not say muscle loss is irrelevant; they argue it is not a complete explanation.
Does this change the current diagnosis of sarcopenia?
No new diagnostic standard is established by the paper. The authors propose that international groups consider a broader framework, while tests they suggest still need validation.
What additional checks do the researchers suggest?
They suggest noting how quickly a person rises from a chair, unsteadiness during sustained effort, hand dexterity and whether walking changes while talking. They also call for closer examination of asymmetric, rapid or disproportionate weakness. These are proposals, not proven replacement tests.
Do the suggested tests reduce falls?
The source report does not present evidence that these measures reduce falls. The authors say it is not yet known whether the proposed approach outperforms current screens on outcomes or cost.
Source: medicalxpress.com
